Admission to Trading on Euronext Brussels
December 18, 2020 05:04 ET
|
Acacia Pharma Group plc
Admission to Trading on Euronext Brussels This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis,...
Publication of Supplementary Prospectus
December 17, 2020 05:15 ET
|
Acacia Pharma Group plc
Publication of Supplementary Prospectus This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis,...
Correction: Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™
December 15, 2020 03:08 ET
|
Acacia Pharma Group plc
Issue price of new ordinary shares to Cosmo in para 8 should be in EUROS rather than GBP and details of Cosmo’s holding post the issue has been added as a final para Correction - Acacia Pharma...
Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™
December 15, 2020 01:46 ET
|
Acacia Pharma Group plc
Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ €5 million commercialization milestone to be paid by Acacia Pharma to Cosmo in New Ordinary...
Director/PDMR Shareholding
October 13, 2020 03:12 ET
|
Acacia Pharma Group plc
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them Cambridge, UK and Indianapolis, US – 13 October...
Director/PDMR Shareholding
October 13, 2020 03:10 ET
|
Acacia Pharma Group plc
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them Cambridge, UK and Indianapolis, US – 13 October...
Issue of Shares to Employee Benefit Trust
October 13, 2020 03:07 ET
|
Acacia Pharma Group plc
Issue of Shares to Employee Benefit Trust This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and...
Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™
October 09, 2020 01:00 ET
|
Acacia Pharma Group plc
Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™ This announcement contains inside information for the...
Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the US
October 06, 2020 10:45 ET
|
Acacia Pharma Group plc
·BYFAVO expected to be commercially available in the US before the end of the year This announcement contains inside information for the purposes of Article 7 of the Market Abuse...
BARHEMSYS® (amisulpride injection) Launched in the US for the Treatment and Prevention of PONV
August 24, 2020 01:00 ET
|
Acacia Pharma Group plc
Acacia Pharma’s BARHEMSYS® (amisulpride injection) Launched and Commercially Available in the US for the Treatment and Prevention of Postoperative Nausea & Vomiting (PONV) This announcement...